Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

726
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
726
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Cancers·2026
Same author

A New Remote Classroom Approach to Contouring Training for Pelvic Malignancies in Low- to Middle-Income Asian Countries.

Cureus·2026
Same author

Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis.

International journal of radiation oncology, biology, physics·2026
Same author

Trends in Long-Term Survival Among Patients With De Novo Metastatic Cancer.

JCO oncology practice·2026
Same author

Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?

International journal of radiation oncology, biology, physics·2026
Same author

Drivers of Variation in the Rate of Radiotherapy Following Lumpectomy in the Military Health System.

Breast cancer (Dove Medical Press)·2026

Related Experiment Video

Updated: May 5, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.7K

Oncology training programs: are we doing comparative effectiveness research justice?

Nicholas G Zaorsky1, Timothy N Showalter

  • 1Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Journal of Comparative Effectiveness Research
|November 19, 2013
PubMed
Summary
This summary is machine-generated.

Oncologic training programs need to improve comparative effectiveness research (CER) education. Enhanced CER training is crucial for physicians to effectively assess medical options and improve patient outcomes.

More Related Videos

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

14.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Experiment Videos

Last Updated: May 5, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.7K
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

14.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Area of Science:

  • Medical Education
  • Health Services Research
  • Oncology

Background:

  • Comparative Effectiveness Research (CER) involves assessing medical options for specific conditions and patient subgroups.
  • Current oncologic training inadequately incorporates CER principles and methodologies.
  • Despite available funding and a clear rationale, CER training in oncology remains minimal.

Purpose of the Study:

  • To highlight the deficiencies in current oncologic training programs regarding CER.
  • To advocate for the integration of CER and patient-centered outcomes research into graduate medical education.

Main Methods:

  • Analysis of current oncologic residency and fellowship curricula.
  • Review of Accreditation Council for Graduate Medical Education (ACGME) guidelines.
  • Assessment of factors limiting CER training emphasis.

Main Results:

  • Oncologic training programs show minimal encouragement for CER.
  • Inadequate emphasis on evidence weighing and lack of explicit CER factors in ACGME guidelines are key limitations.
  • Transition to milestone-based curricula presents an opportunity for CER integration.

Conclusions:

  • Explicit recommendations for CER and patient-centered outcomes research are needed in all oncologic programs.
  • Enhanced CER training will equip physicians to better evaluate treatment options.
  • Trainees proficient in CER will be more competitive for research grants.